Viking Therapeutics (VKTX) Invested Capital (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Invested Capital for 12 consecutive years, with $639.1 million as the latest value for Q4 2025.
- Quarterly Invested Capital fell 27.4% to $639.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $639.1 million through Dec 2025, down 27.4% year-over-year, with the annual reading at $639.1 million for FY2025, 27.4% down from the prior year.
- Invested Capital hit $639.1 million in Q4 2025 for Viking Therapeutics, down from $713.0 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $933.9 million in Q1 2024 to a low of $134.1 million in Q1 2023.
- Historically, Invested Capital has averaged $470.0 million across 5 years, with a median of $358.3 million in 2023.
- Biggest five-year swings in Invested Capital: fell 29.01% in 2022 and later skyrocketed 596.6% in 2024.
- Year by year, Invested Capital stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then skyrocketed by 139.76% to $348.4 million in 2023, then skyrocketed by 152.65% to $880.3 million in 2024, then dropped by 27.4% to $639.1 million in 2025.
- Business Quant data shows Invested Capital for VKTX at $639.1 million in Q4 2025, $713.0 million in Q3 2025, and $795.5 million in Q2 2025.